Manejo de diabetes tipo 2 | 14 MAR 19

Teneligliptina y dieta eficaces en el control de la hiperglucemia

Los autores consideran que la asociación de la teneligliptina con los cambios en los hábitos dietarios mejora el perfil de control de la glucemia en estos pacientes
Autor/a: Kadowaki T, Haneda M, Sasaki K y colaboradore Advances in Therapy 35(6):1-15, Jun 2018
INDICE:  1. Página 1 | 2. Página 2
Página 2


1. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.

2. World Health Organization, Food and Agriculture Organization. Diet, nutrition and the prevention of chronic diseases. Report of a joint WHO/FAO expert consultation. 10665/42665/1/WHO_TRS_916.pdf. Accessed 12 Jan 2018.

3. Guari´guata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–49.

4. National Health and Nutrition Survey in Japan 2016. you-10904750-Kenkoukyoku-Gantaisakukenkou zoushinka/kekkagaiyou_7.pdf. Accessed 12 Jan 2018.

5. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–38.

6. Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8:402–24.

7. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Adv Ther Patients with Obesity. Endocr Pract. 2016;22(Suppl 3):1–203.

8. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–609.

9. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59:1121–40.

10. Watanabe S, Hashimoto E, Ikejima K, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol. 2015;50:364–77.

11. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577–96.

12. Araki E, Haneda M, Kasuga M, et al. New glycemic targets for patients with diabetes from the Japan Diabetes Society. J Diabetes Investig. 2017;8:123–5.

13. American Diabetes Association. Standards of medical care in diabetes—2018. 4. Lifestyle management. Diabetes Care. 2018;41(Suppl 1):S38–50.

14. Bi H, Gan Y, Yang C, Chen Y, Tong X, Lu Z. Breakfast skipping and the risk of type 2 diabetes: a meta-analysis of observational studies. Public Health Nutr. 2015;18:3013–9.

15. Morse SA, Ciechanowski PS, Katon WJ, Hirsch IB. Isn’t this just bedtime snacking? The potential adverse effects of night-eating symptoms on treatment adherence and outcomes in patients with diabetes. Diabetes Care. 2006;29:1800–4.

16. Jakubowicz D, Wainstein J, Ahren B, Landau Z, BarDayan Y, Froy O. Fasting until noon triggers increased postprandial hyperglycemia and impaired insulin response after lunch and dinner in individuals with type 2 diabetes: a randomized clinical trial. Diabetes Care. 2015;38:1820–6.

17. Reutrakul S, Hood MM, Crowley SJ, Morgan MK, Teodori M, Knutson KL. The relationship between breakfast skipping, chronotype, and glycemic control in type 2 diabetes. Chronobiol Int. 2014;31:64–71.

18. Sato M, Nakamura K, Ogata H, et al. Acute effect of late evening meal on diurnal variation of blood glucose and energy metabolism. Obes Res Clin Pract. 2011;5:e220–8.

19. Yabe D, Seino Y, Fukushima M, Seino S. Beta cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diabetes Rep. 2015;15(6):36.

20. Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2012;14:1040–6.

21. Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15:810–8.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2022